SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

CRVO

Cervomed
NEUTRAL
Impact 4/10
Horizonweeks Processed7d 15h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor upcoming data readouts at CTAD 2026 (nfvPPA biomarkers) and RESTORE stroke trial topline results by year-end; these are key catalysts that could validate neflamapimod's broader therapeutic potential beyond DLB. The company's cash runway through Q3 2027 provides visibility but a partnership for DLB Phase 3 is critical for funding and de-risking the program.

DirectionNeutral
Confidencehigh
Horizonweeks

neflamapimod

◆ Mixed Named in this press release
Impact
Phase
Phase 2b completed; Phase 3 planned but not yet initiated
Time to market
At least 3-4 years, assuming a partnership is secured, Phase 3 initiates in H2 2026, completes enrollment and reads out (~2 years), then NDA submission and FDA review (~1 year).
Next catalyst
None dated

What to watchWatch for a strategic partnership announcement to fund the Phase 3 DLB trial, this is the single biggest near-term catalyst and would validate the drug's commercial potential. However, be aware of heavy recent dilution (~$20.5M raised in June 2026), an S-3 resale shelf overhang, and the risk that Phase 3 may not begin without a partner. The stock trades near the low end of its 52-week range ($2.13-$13.13) with a ~$28M market cap; analyst mean target is $19.50 but these targets were set before the latest dilutive financings.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$1.43
T+0 close · Nov 9, 2026 · via day close
Latest settled
+16.78%
T+5 · $1.67
Vs SPY
+18.48%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $1.43entry
  2. T+1 · 7d ago −4.20%α −3.83% · $1.37
  3. T+5 · 16h ago +16.78%α +18.48% · $1.67
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CervoMed reported a Q3 2026 net loss of $5.9M, narrower than the $7.7M loss in Q3 2025, driven by lower R&D spending after the completion of its Phase 2b RewinD-LB trial. The company had $19.6M in cash, expected to fund operations through Q3 2027. Key upcoming catalysts include 24-week biomarker data from the nfvPPA Phase 2a trial at CTAD 2026 and topline data from the RESTORE stroke trial by year-end 2026.

Key Financial Metrics

Revenue
$0.00
est $83.0K · -100.0% · -100.0% YoY

Key Facts

  • Net loss of $5.9M for Q3 2026 vs $7.7M in Q3 2025
  • Cash and marketable securities of $19.6M as of Sep 30, 2026, expected to fund operations through Q3 2027
  • No grant revenue recognized in Q3 2026 vs $0.3M in Q3 2025, due to completion of RewinD-LB trial
  • R&D expenses decreased to $3.7M from $6.0M year-over-year
  • 24-week biomarker data from nfvPPA Phase 2a trial selected for presentation at CTAD 2026 (Nov 16-19)
  • Topline data from Phase 2a RESTORE stroke trial expected by end of 2026
  • First patient dosing in EXPERTS-ALS trial expected in Q1 2027
  • Company seeking strategic partnership to advance neflamapimod into Phase 3 for DLB

Financial Impact

Net loss improved by $1.8M year-over-year; cash burn rate approximately $1.3M per month in Q3 2026

net losscash positionR&D expenses

Risk Factors

  • No revenue and reliance on cash reserves; going concern risk if partnership or financing not secured
  • Clinical trial failure in any of the three ongoing programs (DLB, nfvPPA, RAS, ALS) could impair value
  • Dependence on finding a strategic partner for DLB Phase 3; no guarantee of favorable terms or timing
  • Small market cap ($23M) amplifies volatility on binary clinical events

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398299

Track record

26 reports on CRVO

Performance horizon

12 of 13 bullish or bearish reports moved the stock their way by T+1. Best: +40.68% at T+60 after the Jun 18, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 4/10 Entry $1.74 Now $1.67 −3.75% settles Nov 18
  2. Nov 9, 20267d ago Press Release Neutral 4/10 Viewing Entry $1.43 to $1.37 Now $1.67 +16.78% ▼ −4.20% −3.83% vs SPY
  3. Oct 29, 202618d ago 8-K Neutral 5/10 Entry $1.60 to $1.64 Now $1.67 +4.37% ▲ +2.50% +2.98% vs SPY
  4. Oct 14, 20264w ago 8-K Neutral 2/10 Entry $2.25 to $2.24 Now $1.67 −25.78% ▼ −0.44% +0.66% vs SPY
  5. Oct 13, 20264w ago 8-K Bullish 6/10 Entry $2.27 to $2.29 Now $1.67 −26.43% ▲ +0.88% +1.96% vs SPY
  6. Oct 9, 20265w ago 8-K Neutral 2/10 Entry $2.51 to $2.27 Now $1.67 −33.47% ▼ −9.56% −9.55% vs SPY
  7. Sep 10, 20269w ago Press Release Bullish 5/10 Entry $2.48 to $2.57 Now $1.67 −32.66% ▲ +3.63% +2.78% vs SPY
  8. Aug 10, 202614w ago 8-K Neutral 4/10 Entry $3.09 to $3.07 Now $1.67 −45.95% ▼ −0.65% −0.90% vs SPY
  9. Aug 4, 202614w ago 8-K Bullish 6/10 Entry $2.80 to $2.81 Now $1.67 −40.36% ▲ +0.36% +0.56% vs SPY
  10. Aug 4, 202614w ago Press Release Bullish 4/10 Entry $2.80 to $2.81 Now $1.67 −40.36% ▲ +0.36% +0.56% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (10h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026